$169.99 / month – $1,399.99
Buy FOXO4-DRI 10MG – breakthrough senolytic peptide for anti-aging research. Selectively eliminates senescent cells, promotes cellular health. 99% purity, USA-made, Same Day Shipping.
FOXO4-DRI peptide represents one of the most exciting breakthroughs in anti-aging and longevity research – a senolytic compound specifically designed to eliminate senescent cells, the “zombie cells” that accumulate with age and drive many aspects of biological aging. This revolutionary research peptide is a D-retro-inverso (DRI) modified version of a peptide sequence that disrupts the critical interaction between FOXO4 (Forkhead box O4) transcription factor and p53 tumor suppressor protein, an interaction that keeps senescent cells alive despite their damaged state.
What is foxo4-dri in practical terms? It’s a 29-amino acid peptide composed of D-amino acids (the mirror image of natural L-amino acids) arranged in reverse sequence, creating a highly stable molecule resistant to enzymatic degradation. This DRI modification is crucial – it allows the peptide to remain active in biological systems long enough to reach senescent cells and exert its effects, while natural peptides would be rapidly broken down by proteases.
Cellular senescence is a state in which cells stop dividing but don’t die, instead persisting in a dysfunctional state. While senescence serves important purposes in young organisms (preventing cancer, aiding wound healing), senescent cells accumulate with age and become harmful. These cells secrete inflammatory factors, growth factors, and proteases – collectively called the senescence-associated secretory phenotype (SASP) – that damage surrounding tissues, promote chronic inflammation, and contribute to age-related diseases including cancer, cardiovascular disease, neurodegeneration, and metabolic disorders.
The foxo4-dri senolytic peptide works by exploiting a vulnerability specific to senescent cells. In these cells, FOXO4 binds to p53 and keeps it sequestered in the nucleus, preventing p53 from triggering apoptosis (programmed cell death). This FOXO4-p53 interaction is essential for senescent cell survival – without it, the extensive DNA damage and cellular stress in senescent cells would normally trigger p53-mediated apoptosis. FOXO4-DRI competitively binds to p53, displacing FOXO4 and allowing p53 to relocate to mitochondria where it initiates the apoptotic cascade, selectively eliminating senescent cells.
The selectivity of foxo4 dri is remarkable and crucial for its safety. Healthy cells don’t rely on the FOXO4-p53 interaction for survival, so they remain unaffected by the peptide. Only senescent cells, which depend on this interaction to avoid apoptosis despite their damaged state, are eliminated. This selective senolytic activity makes FOXO4-DRI a precision tool for targeting cellular aging at its source.
Research with foxo4-dri peptide has demonstrated impressive results in preclinical studies. In aged mice, treatment with FOXO4-DRI led to clearance of senescent cells from multiple tissues, restoration of more youthful tissue function, improvements in physical fitness and endurance, enhanced fur density and quality (suggesting effects on stem cell function), improved kidney function, and extended healthspan. Remarkably, these benefits were achieved with intermittent dosing – just a few days of treatment followed by weeks or months off, allowing time for senescent cell clearance and tissue regeneration.
The foxo4-dri human trials represent some of the most exciting developments in longevity research. While human data remains limited, early trials have shown promising results including improvements in kidney function markers in aged subjects, enhanced hair growth and quality, better physical performance and stamina, improvements in various age-related biomarkers, and subjective improvements in energy and well-being. These early human results, combined with extensive preclinical data, suggest that FOXO4-DRI may be one of the first truly effective anti-aging interventions targeting a fundamental mechanism of aging.
For researchers studying aging, longevity, and age-related diseases, foxo4 dri offers unique advantages. The peptide provides a tool for investigating the role of senescent cells in various pathological processes, testing the senolytic hypothesis of aging, exploring tissue regeneration and rejuvenation mechanisms, and developing potential therapeutic approaches to age-related diseases. The ability to selectively eliminate senescent cells allows researchers to study their contributions to aging and disease in ways not previously possible.
When researchers buy foxo4-dri from PrymaLab, they receive pharmaceutical-grade peptide manufactured to the highest quality standards. Each FOXO4-DRI 10MG vial contains 99% pure peptide verified by third-party testing, ensuring reliable and reproducible research results. The peptide arrives as lyophilized powder for maximum stability, ready for reconstitution with bacteriostatic water when research protocols begin.
The development of foxo4-dri senolytic peptide stems from groundbreaking research by Dr. Peter de Keizer and colleagues at the Erasmus University Medical Center in the Netherlands. Their work identifying the FOXO4-p53 interaction as a therapeutic target for senescent cell elimination, and developing a peptide to disrupt this interaction, represents a major advance in aging research. The peptide has been featured in high-profile scientific publications and has generated significant interest in the longevity research community.
Understanding the broader context of senolytic research helps appreciate the significance of foxo4 peptide. Senolytics – compounds that selectively eliminate senescent cells – represent a new class of potential anti-aging interventions. While other senolytics exist (including dasatinib + quercetin, fisetin, and navitoclax), FOXO4-DRI offers advantages in terms of selectivity, mechanism of action, and potentially safety profile. The peptide-based approach allows for precise targeting of the FOXO4-p53 interaction, potentially providing superior selectivity compared to small molecule senolytics that may have broader effects.
To fully appreciate how foxo4-dri works, it’s essential to understand cellular senescence and its role in aging. Cellular senescence is a state of permanent cell cycle arrest accompanied by distinctive changes in cell morphology, metabolism, and secretory profile. Senescent cells are metabolically active but no longer divide, and they resist apoptosis despite accumulating damage.
Senescence can be triggered by various stresses including telomere shortening (replicative senescence), DNA damage, oxidative stress, oncogene activation, and mitochondrial dysfunction. When cells experience these stresses, they activate senescence programs as a protective mechanism. In young organisms, senescence serves important functions including preventing cancer (by stopping damaged cells from dividing), aiding wound healing (through SASP factors that recruit immune cells), and supporting tissue remodeling during development.
However, the accumulation of senescent cells with age becomes problematic. While young organisms efficiently clear senescent cells through immune surveillance, this clearance becomes less efficient with aging. Senescent cells accumulate in tissues, and their SASP factors create a pro-inflammatory, tissue-damaging environment. The SASP includes inflammatory cytokines (IL-6, IL-8, IL-1α), growth factors (VEGF, HGF), proteases (MMPs), and other factors that affect surrounding cells and tissues.
The harmful effects of accumulated senescent cells are extensive. They promote chronic inflammation (“inflammaging”), a hallmark of aging associated with numerous age-related diseases. They impair tissue regeneration by affecting stem cell function and creating a hostile microenvironment. They contribute to tissue dysfunction through SASP-mediated damage to surrounding cells. They can induce senescence in neighboring cells through paracrine effects, spreading cellular aging. They promote age-related pathologies including atherosclerosis, osteoarthritis, neurodegeneration, and cancer.
The “senescence hypothesis of aging” proposes that accumulated senescent cells are a primary driver of biological aging and age-related diseases. This hypothesis is supported by extensive research showing that eliminating senescent cells in aged mice extends healthspan, delays age-related diseases, improves physical function, and even extends lifespan. These findings have made senescent cells a major target for anti-aging interventions.
FOXO4-DRI peptide represents a sophisticated approach to targeting senescent cells. Rather than broadly affecting cell survival pathways, it specifically disrupts a protein-protein interaction that senescent cells uniquely depend on. This precision targeting is what makes foxo4-dri senolytic activity so selective and potentially safe.
The FOXO4 transcription factor belongs to the Forkhead box O (FOXO) family of proteins that regulate various cellular processes including stress resistance, metabolism, and cell survival. In senescent cells, FOXO4 plays a crucial role in maintaining the senescent state by binding to p53 and preventing it from triggering apoptosis. This interaction is particularly important in senescent cells because they have extensive DNA damage and cellular stress that would normally activate p53-mediated cell death.
The p53 protein is often called the “guardian of the genome” because it responds to cellular stress and DNA damage by either promoting DNA repair or triggering apoptosis if damage is too severe. In healthy cells, p53 levels are kept low, but stress activates p53, leading to cell cycle arrest, DNA repair, or apoptosis depending on the severity of damage. In senescent cells, p53 is activated by extensive damage, but FOXO4 prevents it from triggering apoptosis, allowing senescent cells to persist.
FOXO4-DRI disrupts this protective interaction. By competitively binding to p53, the peptide displaces FOXO4, allowing p53 to relocate from the nucleus to mitochondria. At mitochondria, p53 triggers the intrinsic apoptotic pathway, leading to selective elimination of senescent cells. This mechanism is elegant in its selectivity – healthy cells don’t depend on the FOXO4-p53 interaction, so they’re unaffected by foxo4 dri.
The foxo4-dri mechanism of action involves a sophisticated molecular process that selectively targets senescent cells while sparing healthy cells. Understanding this mechanism helps researchers design effective protocols and interpret research results.
Primary Mechanism – FOXO4-p53 Interaction Disruption:
When FOXO4-DRI is administered, it enters the bloodstream and distributes throughout the body. The peptide’s D-retro-inverso structure makes it highly resistant to proteolytic degradation, allowing it to remain active long enough to reach target tissues. The peptide can penetrate cell membranes through various mechanisms including direct penetration and endocytosis, reaching the intracellular compartment where FOXO4 and p53 interact.
Inside cells, foxo4-dri peptide competitively binds to p53, specifically targeting the binding interface between FOXO4 and p53. The peptide sequence was designed based on the FOXO4 region that interacts with p53, allowing it to mimic this interaction and displace FOXO4. The DRI modification ensures the peptide maintains binding affinity while resisting degradation.
Selective Senescent Cell Targeting:
The selectivity of foxo4 dri for senescent cells is crucial for its safety and effectiveness. In healthy cells, the FOXO4-p53 interaction is not critical for survival. These cells have low levels of cellular stress and DNA damage, so p53 is not strongly activated. Even if FOXO4-DRI disrupts any FOXO4-p53 interactions in healthy cells, this doesn’t trigger apoptosis because p53 is not in an activated, pro-apoptotic state.
In senescent cells, the situation is dramatically different. These cells have extensive DNA damage, oxidative stress, and cellular dysfunction that strongly activate p53. Under normal circumstances, this activated p53 would trigger apoptosis, but FOXO4 prevents this by sequestering p53 in the nucleus. The FOXO4-p53 interaction is essential for senescent cell survival – it’s the key mechanism preventing these damaged cells from undergoing apoptosis.
When foxo4-dri senolytic peptide disrupts the FOXO4-p53 interaction in senescent cells, it removes this critical survival mechanism. The activated p53, no longer held in check by FOXO4, can now fulfill its pro-apoptotic function. P53 translocates from the nucleus to mitochondria, where it triggers the intrinsic apoptotic pathway.
P53-Mediated Apoptosis:
At mitochondria, p53 interacts with pro-apoptotic proteins including BAX and BAK, promoting their oligomerization and insertion into the mitochondrial outer membrane. This creates pores that allow cytochrome c and other pro-apoptotic factors to be released from mitochondria into the cytoplasm. Cytochrome c activates caspases, the executioner enzymes of apoptosis, leading to systematic dismantling of the cell.
The apoptotic process triggered by FOXO4-DRI in senescent cells is orderly and immunologically silent, unlike necrotic cell death which causes inflammation. Apoptotic cells are efficiently cleared by phagocytes without triggering inflammatory responses. This clean elimination of senescent cells is important for the therapeutic potential of foxo4 dri.
Tissue-Level Effects:
The elimination of senescent cells by foxo4-dri peptide has profound effects at the tissue level. Removal of senescent cells eliminates the source of SASP factors, reducing chronic inflammation and tissue damage. The improved tissue environment supports regeneration and repair, as stem cells and progenitor cells can function better without SASP-mediated inhibition. Tissues show improved function as damaged, dysfunctional senescent cells are replaced through normal turnover and regeneration.
Research has shown that FOXO4-DRI treatment leads to clearance of senescent cells from multiple tissues including kidney, liver, lung, and skin. The extent of clearance varies by tissue and dosing protocol, but significant reductions in senescent cell burden have been documented. Importantly, the clearance is selective – markers of senescence decrease while overall tissue cellularity and function improve, indicating that healthy cells are preserved.
Timing and Kinetics:
The kinetics of foxo4-dri action are important for protocol design. After administration, the peptide reaches peak concentrations in tissues within hours. Senescent cell apoptosis begins within the first day of treatment and continues over several days. Clearance of apoptotic cells by phagocytes occurs over days to weeks. Tissue regeneration and functional improvements develop over weeks to months following senescent cell clearance.
This timeline explains why foxo4-dri dosage protocols typically use intermittent dosing – a few days of treatment followed by weeks or months off. The initial treatment triggers senescent cell apoptosis, and the off period allows time for clearance and tissue regeneration. Repeated cycles can be used to address senescent cells that accumulate over time or weren’t eliminated in previous cycles.
Dose-Response Relationship:
Research has established dose-dependent effects for foxo4-dri peptide. Higher doses generally produce greater senescent cell clearance, though there appears to be a plateau effect where additional increases provide diminishing returns. The optimal dose balances efficacy (sufficient senescent cell elimination) with safety (minimizing any potential effects on healthy cells).
Most research uses doses calculated based on body weight or surface area, with preclinical studies using doses in the range of 5-25 mg/kg in mice. Translating these doses to humans using standard scaling methods suggests doses in the range of 5-15mg per administration for a 70kg person, though human dosing remains an active area of research.
Selectivity Mechanisms:
The remarkable selectivity of foxo4 dri for senescent cells results from multiple factors. Senescent cells have higher levels of activated p53 due to extensive DNA damage and stress. They depend critically on the FOXO4-p53 interaction for survival, while healthy cells don’t. Senescent cells may have enhanced peptide uptake due to altered membrane properties. The threshold for p53-mediated apoptosis is lower in senescent cells due to accumulated damage.
These factors combine to create a therapeutic window where FOXO4-DRI can eliminate senescent cells at doses that don’t significantly affect healthy cells. This selectivity is what makes foxo4-dri senolytic peptide so promising as a potential anti-aging intervention.
The foxo4-dri benefits extend across multiple aspects of aging biology and healthspan, making it one of the most exciting compounds in longevity research. Understanding these benefits helps researchers design studies that maximize the peptide’s research value and translational potential.
Senescent Cell Clearance:
The primary and most direct benefit of foxo4-dri peptide is elimination of senescent cells from tissues. Research has demonstrated significant reductions in senescent cell burden across multiple tissues including kidney, liver, lung, skin, and adipose tissue. The clearance is selective, with senescent cell markers (p16, p21, SA-β-gal) decreasing while overall tissue cellularity is maintained or improved. The extent of clearance varies by tissue and protocol but can be substantial, with some studies showing 50-70% reductions in senescent cell numbers.
Reduced Inflammation:
Elimination of senescent cells removes the source of SASP factors, leading to significant reductions in chronic inflammation. Research shows decreases in inflammatory cytokines (IL-6, IL-8, IL-1α), reduced markers of systemic inflammation (CRP, inflammatory gene expression), improvements in inflammatory signaling pathways, and better immune system function. The anti-inflammatory effects of foxo4 dri are particularly important because chronic inflammation (“inflammaging”) is a major driver of age-related diseases and functional decline.
Improved Tissue Function:
The foxo4-dri benefits include improvements in function across multiple organ systems. Kidney function improvements have been documented in both preclinical and early human studies, with better filtration rates and reduced markers of kidney damage. Cardiovascular improvements include better vascular function and reduced arterial stiffness. Metabolic health benefits include improved glucose metabolism and insulin sensitivity. Liver function improvements show reduced fat accumulation and better metabolic function. Physical performance enhancements include better endurance, strength, and mobility.
Enhanced Tissue Regeneration:
By removing senescent cells and their inhibitory SASP factors, foxo4-dri peptide creates an environment more conducive to tissue regeneration. Research shows enhanced stem cell function and proliferation, improved tissue repair and wound healing, better regenerative capacity in aged tissues, and restoration of more youthful tissue architecture. The regenerative effects are particularly impressive in tissues with high regenerative capacity like skin, liver, and muscle.
Improved Physical Function:
One of the most striking foxo4 dri peptide benefits in preclinical research is improvement in physical function and performance. Aged mice treated with FOXO4-DRI showed increased running endurance and distance, improved grip strength and muscle function, better coordination and balance, enhanced overall physical activity levels, and restoration of more youthful movement patterns. These functional improvements suggest that senescent cell clearance has meaningful effects on healthspan and quality of life.
Hair and Fur Quality:
Interestingly, research has shown improvements in hair and fur quality with foxo4-dri treatment. Aged mice showed increased fur density and coverage, restoration of more youthful fur color and texture, and enhanced hair follicle function. These effects likely reflect improved stem cell function in hair follicles, as senescent cells in the follicle niche can impair stem cell activity. While cosmetic, these changes serve as visible markers of the peptide’s effects on tissue aging and regeneration.
Cognitive and Neurological Benefits:
Emerging research suggests foxo4-dri senolytic peptide may have benefits for brain health and cognitive function. Preclinical studies show reduced neuroinflammation, improved cognitive performance in aged animals, better neuronal function and synaptic plasticity, and potential neuroprotective effects. These findings are particularly exciting given the role of senescent cells in neurodegenerative diseases and cognitive decline.
Metabolic Health Improvements:
FOXO4-DRI produces beneficial effects on metabolic health including improved glucose tolerance and insulin sensitivity, better lipid profiles with reduced triglycerides, reduced fat accumulation in liver and other tissues, improved metabolic rate and energy expenditure, and better overall metabolic function. These metabolic benefits likely result from reduced inflammation and improved tissue function following senescent cell clearance.
Cardiovascular Benefits:
Research indicates foxo4 dri may improve cardiovascular health through reduced vascular inflammation, improved endothelial function and vascular reactivity, reduced arterial stiffness and improved compliance, better cardiac function in aged hearts, and reduced risk factors for cardiovascular disease. Given that cardiovascular disease is a leading cause of death and disability in aging, these cardiovascular benefits are particularly important.
Bone and Joint Health:
Senescent cells accumulate in bone and cartilage with age, contributing to osteoporosis and osteoarthritis. FOXO4-DRI peptide research shows improved bone density and strength, better cartilage health and reduced arthritis symptoms, enhanced bone formation and reduced resorption, and improved joint function and mobility. These musculoskeletal benefits could have major implications for maintaining independence and quality of life in aging.
Cancer Prevention Potential:
While requiring careful research, foxo4-dri may have cancer prevention benefits. Senescent cells can promote cancer through SASP factors that create a pro-tumorigenic microenvironment. Eliminating senescent cells may reduce cancer risk by removing this pro-tumorigenic influence, reducing chronic inflammation that promotes cancer, and improving immune surveillance of pre-cancerous cells. However, the relationship between senescence and cancer is complex, as senescence also serves as a tumor suppressor mechanism. Research in this area continues.
Lifespan and Healthspan Extension:
Perhaps the most exciting foxo4-dri benefits are effects on lifespan and healthspan. Preclinical research in mice has shown extended healthspan with delayed onset of age-related diseases, improved quality of life in aged animals, potential lifespan extension in some studies, and compression of morbidity (shorter period of age-related illness). While human lifespan data doesn’t exist, the improvements in multiple health parameters suggest potential for healthspan extension in humans.
Intermittent Dosing Advantages:
A unique advantage of foxo4-dri senolytic peptide is that benefits can be achieved with intermittent dosing. Unlike interventions requiring continuous administration, FOXO4-DRI can be given for just a few days, with benefits lasting weeks or months. This intermittent approach reduces total exposure, potentially improving safety, is more convenient for research subjects, and may be more cost-effective than continuous treatments.
Research Versatility:
The diverse foxo4 peptide benefits make it suitable for numerous research applications including fundamental aging research, age-related disease studies, tissue regeneration research, longevity intervention studies, healthspan optimization research, and translational medicine development. This versatility makes FOXO4-DRI one of the most valuable compounds in the longevity research arsenal.
FOXO4-DRI has been studied in both preclinical and early human research, providing substantial data on its effects, safety profile, and potential applications. Understanding this research history helps researchers design effective protocols and interpret findings in context.
Preclinical Development:
The development of foxo4-dri peptide began with research by Dr. Peter de Keizer and colleagues at Erasmus University Medical Center in the Netherlands. Their groundbreaking 2017 paper in Cell identified the FOXO4-p53 interaction as a therapeutic target for senescent cell elimination and demonstrated that a peptide disrupting this interaction could selectively eliminate senescent cells.
Initial studies in cell culture showed that FOXO4-DRI selectively induced apoptosis in senescent cells while sparing proliferating and quiescent cells. The selectivity was remarkable – senescent cells showed dose-dependent apoptosis, while healthy cells remained viable even at high peptide concentrations. This in vitro work established the proof-of-concept for foxo4-dri senolytic activity.
Animal Studies – Aged Mice:
The most impressive preclinical data comes from studies in naturally aged mice. In these experiments, old mice (approximately 24 months old, equivalent to 70+ year old humans) were treated with FOXO4-DRI for 3 consecutive days, then observed for weeks to months. Results were striking including significant improvements in physical fitness and running endurance, restoration of more youthful fur density and quality, improved kidney function with reduced markers of kidney damage, better overall health and vitality, and extended healthspan with delayed age-related decline.
Remarkably, these benefits were achieved with just 3 days of treatment, demonstrating the power of senescent cell clearance. The improvements persisted for months after treatment, suggesting that eliminating senescent cells creates lasting benefits through improved tissue regeneration and reduced chronic inflammation.
Tissue-Specific Studies:
Research has examined foxo4 dri effects in specific tissues and organs. Kidney studies showed reduced senescent cell burden in aged kidneys, improved glomerular filtration and kidney function, reduced fibrosis and tissue damage, and restoration of more youthful kidney architecture. Liver research demonstrated clearance of senescent hepatocytes, reduced fat accumulation and improved metabolic function, better liver regenerative capacity, and improved overall liver health. Cardiovascular studies showed reduced vascular senescent cells, improved endothelial function and vascular reactivity, reduced arterial stiffness, and better cardiac function in aged hearts.
Disease Model Studies:
FOXO4-DRI peptide has been studied in various disease models to understand its therapeutic potential. In models of chemotherapy-induced senescence, the peptide cleared therapy-induced senescent cells, reduced side effects of chemotherapy, and potentially improved treatment outcomes. Metabolic disease models showed improved glucose metabolism and insulin sensitivity, reduced fat accumulation and metabolic dysfunction, and better overall metabolic health. Osteoarthritis models demonstrated reduced cartilage senescent cells, improved joint function and reduced pain, and slowed disease progression.
Mechanism Studies:
Detailed mechanistic research has confirmed how foxo4-dri works. Studies show the peptide disrupts FOXO4-p53 binding in senescent cells, allows p53 translocation to mitochondria, triggers intrinsic apoptotic pathway activation, and selectively eliminates senescent cells while sparing healthy cells. Molecular studies have mapped the binding interface and confirmed the mechanism of action.
Dosing and Protocol Studies:
Research exploring optimal foxo4-dri dosage has provided guidance for protocol design. Studies comparing different doses show dose-dependent senescent cell clearance, with higher doses generally more effective but with diminishing returns at very high doses. Timing studies indicate that 2-3 consecutive days of dosing is effective, with benefits lasting weeks to months. Repeated cycle studies show that multiple treatment cycles can be used safely and effectively.
Human Trials:
The foxo4-dri human trials represent some of the most exciting developments in longevity research, though data remains limited. Early human studies have been conducted, primarily in the Netherlands, with promising preliminary results. While detailed published data is limited, reports suggest improvements in kidney function markers in aged subjects, enhanced hair growth and quality, better physical performance and stamina, improvements in various age-related biomarkers, and subjective improvements in energy and well-being.
The foxo4-dri human trials have used various dosing regimens, typically involving several days of treatment followed by observation periods. Safety monitoring has shown generally good tolerability with mostly mild and transient side effects. These early human results, while preliminary, suggest that the impressive preclinical findings may translate to humans.
Ongoing Research:
Current research with foxo4 dri peptide continues to explore its potential applications. Studies are investigating optimal dosing regimens for different applications, long-term safety and efficacy, effects in specific age-related diseases, combination with other longevity interventions, and mechanisms of tissue regeneration following senescent cell clearance. The field of senolytic research is rapidly evolving, with FOXO4-DRI at the forefront.
Comparative Studies:
Research comparing foxo4-dri senolytic peptide to other senolytics has provided insights into relative effectiveness. Studies comparing to dasatinib + quercetin (D+Q) show that FOXO4-DRI may have superior selectivity for senescent cells, potentially fewer side effects, and different tissue distribution and effects. Comparisons to fisetin indicate that FOXO4-DRI may be more potent on a per-dose basis and has a different mechanism allowing for complementary effects. Studies versus navitoclax show that FOXO4-DRI has a better safety profile with fewer hematological effects.
Publication History:
The landmark 2017 Cell paper by Baar et al. titled “Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging” put FOXO4-DRI on the map. This high-profile publication demonstrated the peptide’s senolytic activity and its effects in aged mice, generating significant interest in the longevity research community. Subsequent publications have explored mechanisms, applications, and translational potential.
Future Directions:
The future of foxo4 dri research is promising. Planned and ongoing studies include larger human trials with more comprehensive outcome measures, studies in specific age-related diseases, investigation of combination therapies with other longevity interventions, development of optimized dosing protocols, and exploration of tissue-specific delivery methods. The peptide represents a new frontier in aging research and potential therapeutic development.
Researchers often compare foxo4-dri to other senolytic compounds to understand which approach best suits their research needs. Understanding the differences between FOXO4-DRI and alternatives helps researchers make informed decisions about study design and compound selection.
FOXO4-DRI vs Dasatinib + Quercetin (D+Q):
Dasatinib + quercetin is the most studied senolytic combination, making it an important comparison point for foxo4-dri senolytic peptide. D+Q works through different mechanisms – dasatinib is a tyrosine kinase inhibitor that affects multiple survival pathways, while quercetin is a flavonoid with various effects including inhibition of anti-apoptotic proteins. Together, they can eliminate senescent cells, though with less selectivity than FOXO4-DRI.
Key differences include mechanism of action (FOXO4-DRI targets specific FOXO4-p53 interaction vs D+Q’s broader pathway effects), selectivity (FOXO4-DRI appears more selective for senescent cells), side effects (D+Q can cause more side effects due to broader activity), administration (FOXO4-DRI requires injection vs D+Q oral administration), and research status (D+Q has more human data but FOXO4-DRI shows promising early results).
Research suggests foxo4 dri may offer advantages in selectivity and potentially safety, while D+Q has the advantage of oral administration and more extensive human safety data. The choice between them often depends on specific research objectives and practical considerations.
FOXO4-DRI vs Fisetin:
Fisetin is a natural flavonoid with senolytic properties, making it another important comparison. Fisetin works by inhibiting multiple survival pathways in senescent cells, including PI3K/AKT and BCL-2 family proteins. It’s orally bioavailable and has a good safety profile as a natural compound.
Comparing foxo4-dri peptide to fisetin reveals differences in potency (FOXO4-DRI appears more potent on a per-dose basis), selectivity (FOXO4-DRI more selective for senescent cells), mechanism (FOXO4-DRI targets specific interaction vs fisetin’s broader effects), administration (FOXO4-DRI injection vs fisetin oral), and cost (fisetin generally less expensive as natural compound).
Some researchers explore combining FOXO4-DRI with fisetin, as their different mechanisms might provide complementary senolytic effects. The combination could potentially clear senescent cells more completely than either compound alone.
FOXO4-DRI vs Navitoclax:
Navitoclax is a BCL-2 family inhibitor with potent senolytic activity. It works by inhibiting anti-apoptotic proteins that senescent cells depend on for survival. While effective, navitoclax has significant side effects, particularly thrombocytopenia (low platelet counts), limiting its use.
The comparison shows that foxo4-dri senolytic offers better selectivity with fewer effects on healthy cells, superior safety profile without significant hematological effects, different mechanism allowing for potential combination use, and potentially better tolerability for research applications. Navitoclax’s main advantage is its potency and extensive characterization, but safety concerns limit its utility.
FOXO4-DRI vs Other Peptide Senolytics:
Other peptide-based senolytics are in development, though foxo4 dri peptide remains the most studied. Comparisons to emerging peptide senolytics will be important as the field develops. The peptide approach offers advantages including high selectivity for specific targets, potential for optimization through sequence modification, and ability to target intracellular protein-protein interactions.
Combination Approaches:
An exciting area of research is combining foxo4-dri with other senolytics or longevity interventions. Potential combinations include FOXO4-DRI + fisetin for complementary senolytic mechanisms, FOXO4-DRI + NAD+ precursors for combined senolytic and metabolic benefits, FOXO4-DRI + rapamycin for senolytic plus autophagy enhancement, and FOXO4-DRI + metformin for combined anti-aging approaches.
These combinations could potentially provide synergistic benefits, though they require careful research to establish safety and optimal protocols.
Choosing the Right Senolytic:
The choice between foxo4-dri and other senolytics depends on specific research objectives:
Many researchers find value in having multiple senolytics available for comparison studies or combination research. All of these approaches are valuable tools in the longevity research arsenal, with foxo4-dri senolytic peptide offering unique advantages in selectivity and mechanism.
Determining appropriate foxo4-dri dosage for research applications requires understanding the available preclinical and early human data, considering research goals, and accounting for the unique intermittent dosing strategy used with senolytic compounds. Unlike peptides requiring continuous administration, FOXO4-DRI is typically used in short cycles followed by extended off periods.
Animal research with foxo4-dri peptide has established dosing ranges and protocols:
Mouse Studies:
Dose Scaling to Humans:
Translating animal doses to humans using standard allometric scaling methods:
Based on available data, research protocols with foxo4-dri dosage typically consider:
Conservative Research Protocol:
Standard Research Protocol:
Advanced Research Protocol:
Comprehensive foxo4 dri dosage chart for research:
| Research Goal | Dose per Day | Duration | Cycle Frequency | Total per Cycle |
|---|---|---|---|---|
| Conservative/Initial | 5-10mg | 2-3 days | Single cycle | 10-30mg |
| Standard Senolytic | 10-15mg | 3 days | Every 3-6 months | 30-45mg |
| Advanced Protocol | 15-20mg | 3 days | Every 3-6 months | 45-60mg |
| Weight-Based (0.15mg/kg) | Calculate | 3 days | Every 3-6 months | Varies |
The foxo4-dri dosage approach differs fundamentally from continuous peptide administration:
Why Intermittent Dosing:
Typical Cycle Structure:
Treatment Phase (Days 1-3):
Observation Phase (Weeks 1-12+):
Repeat Cycle (If Needed):
For researchers working with FOXO4-DRI 10MG vials, accurate dosage calculations are essential:
Example Calculation for 10mg Dose:
Standard dose (10mg):
Example Calculation for 15mg Dose:
Higher dose (15mg):
Example for Weight-Based Dosing:
For 70kg subject at 0.15mg/kg:
Proper reconstitution of foxo4-dri is essential:
Reconstitution Steps:
Proper subcutaneous injection technique for foxo4-dri peptide:
Injection Sites:
Injection Procedure:
Best Time for Administration:
Morning Dosing:
Fasted vs Fed State:
Cycle Timing:
Proper storage maintains foxo4-dri potency:
Unreconstituted Peptide:
Reconstituted Solution:
Handling Precautions:
When designing research protocols with foxo4-dri dosage:
Single Cycle Studies:
Multiple Cycle Studies:
Dose-Response Studies:
Monitoring Parameters:
FOXO4-DRI Human Dosage:
The foxo4-dri human dosage remains an active area of research. Early human trials have used various doses, generally in the range of 5-20mg per administration. Optimal human dosing continues to be refined through ongoing research.
Body Weight Considerations:
Some protocols calculate doses based on body weight:
Age Considerations:
Older subjects may have:
PrymaLab provides comprehensive support for researchers using foxo4-dri:
When researchers buy foxo4-dri from PrymaLab, they receive detailed reconstitution and administration instructions with their order, ensuring proper handling and use of this valuable senolytic research compound.
The foxo4 dri side effects profile is based on preclinical research and limited early human data. While the peptide has shown a generally favorable safety profile, understanding potential effects is crucial for responsible research use and appropriate safety monitoring.
Animal Studies:
Research in mice has provided extensive safety data for foxo4-dri peptide:
Common Observations:
Laboratory Changes:
Long-Term Safety:
The foxo4-dri human trials, while limited, have provided preliminary human safety data:
Reported Effects:
Common (Mild and Transient):
Laboratory Changes:
Serious Adverse Events:
Injection Site Reactions:
The most common foxo4 dri side effects are injection site reactions:
Fatigue:
Some subjects report mild fatigue:
Headaches:
Occasional reports of mild headaches:
Gastrointestinal Symptoms:
Rare reports of mild GI symptoms:
Senescent Cell Functions:
While most senescent cells are harmful in aging, some may serve beneficial functions:
The foxo4-dri senolytic peptide selectivity for chronically senescent cells (not acutely senescent cells involved in wound healing) may mitigate these concerns. Research suggests benefits of clearing harmful senescent cells outweigh potential loss of beneficial functions.
Cancer Considerations:
The relationship between senescence and cancer is complex:
Research suggests foxo4-dri may reduce cancer risk by eliminating pro-tumorigenic senescent cells, but this area requires continued study.
Immune System Effects:
Clearing senescent cells requires immune system involvement:
The foxo4-dri side effects profile compares favorably to other senolytics:
Compared to Dasatinib + Quercetin:
Compared to Navitoclax:
Compared to Fisetin:
Certain conditions warrant extra caution with foxo4-dri:
Absolute Contraindications:
Relative Contraindications:
Special Populations:
Elderly Subjects:
Subjects with Chronic Diseases:
Researchers using foxo4-dri peptide should implement appropriate monitoring:
Baseline Assessment:
During Treatment Cycle:
Post-Treatment Monitoring:
Warning Signs:
If foxo4-dri side effects occur:
For Injection Site Reactions:
For Fatigue:
For Headaches:
General Management:
Repeated Cycle Safety:
Research suggests foxo4-dri maintains good safety with repeated cycles:
Duration Recommendations:
Regulatory Status:
Research Ethics:
To minimize risks when conducting research with foxo4-dri:
Protocol Design:
Subject Selection:
Monitoring and Follow-Up:
Quality Assurance:
When researchers buy foxo4-dri from PrymaLab, comprehensive safety information is provided with each order, including known side effects, monitoring recommendations, and management guidelines. This ensures researchers have the information needed for responsible and safe research use of this promising senolytic compound.
FOXO4-DRI peptide is a revolutionary senolytic compound designed to selectively eliminate senescent cells – the “zombie cells” that accumulate with age and drive many aspects of biological aging. It’s a D-retro-inverso (DRI) modified peptide consisting of 29 amino acids composed of D-amino acids in reverse sequence, making it highly resistant to enzymatic degradation. What is foxo4-dri in terms of mechanism? It disrupts the critical interaction between FOXO4 transcription factor and p53 tumor suppressor protein in senescent cells, allowing p53 to trigger apoptosis specifically in these damaged cells while leaving healthy cells unharmed. This selective senolytic activity makes foxo4-dri senolytic peptide one of the most promising anti-aging interventions currently in research. The peptide was developed by Dr. Peter de Keizer and colleagues at Erasmus University Medical Center, with groundbreaking research published in Cell in 2017. Preclinical studies in aged mice showed remarkable rejuvenation effects including improved physical fitness, restored fur quality, better kidney function, and extended healthspan. Early foxo4-dri human trials have shown promising results including improvements in kidney function, enhanced hair growth, and better overall health markers. When researchers buy foxo4-dri from PrymaLab, they receive pharmaceutical-grade peptide with 99% purity, ideal for senolytic and anti-aging research.
FOXO4-DRI works through a sophisticated mechanism that selectively targets senescent cells. In senescent cells, FOXO4 protein binds to p53 and keeps it sequestered in the nucleus, preventing p53 from triggering apoptosis despite extensive cellular damage. This FOXO4-p53 interaction is essential for senescent cell survival – it’s what allows these damaged cells to persist indefinitely. Foxo4-dri peptide competitively binds to p53, displacing FOXO4 and allowing p53 to relocate from the nucleus to mitochondria. At mitochondria, p53 triggers the intrinsic apoptotic pathway, leading to selective elimination of senescent cells. The remarkable selectivity of foxo4 dri comes from the fact that healthy cells don’t depend on the FOXO4-p53 interaction for survival, so they remain unaffected by the peptide. Only senescent cells, which rely on this interaction to avoid apoptosis despite their damaged state, are eliminated. The foxo4-dri senolytic mechanism represents a precision approach to targeting cellular aging at its source. After senescent cells are eliminated, tissues show reduced inflammation (as SASP factors are no longer produced), improved regenerative capacity, better function, and restoration of more youthful characteristics. The D-retro-inverso structure of the peptide makes it highly stable in biological systems, allowing it to remain active long enough to reach senescent cells and exert its effects.
The foxo4-dri benefits are extensive and impressive based on preclinical and early human research. Primary benefits include selective elimination of senescent cells from multiple tissues, significant reductions in chronic inflammation and SASP factors, improvements in tissue function across multiple organ systems, enhanced tissue regeneration and repair capacity, better physical performance including endurance and strength, improvements in kidney function and metabolic health, enhanced hair growth and quality (reflecting improved stem cell function), better cardiovascular function and vascular health, improvements in age-related biomarkers, and subjective improvements in energy and well-being. The foxo4 dri peptide benefits extend beyond simple senescent cell clearance to comprehensive tissue rejuvenation. Research in aged mice showed dramatic improvements including restored physical fitness, better fur density and quality, improved kidney function, enhanced overall health and vitality, and extended healthspan with delayed age-related decline. The foxo4-dri benefits are achieved with intermittent dosing – just 2-3 days of treatment can produce benefits lasting weeks to months. This intermittent approach reduces total exposure while maintaining efficacy. The foxo4 peptide benefits make it one of the most exciting compounds in longevity research, offering a targeted approach to addressing cellular aging at its source. When researchers buy foxo4-dri from PrymaLab, they access a powerful tool for studying senescence, aging, and potential anti-aging interventions.
The recommended foxo4-dri dosage is based on preclinical research and limited early human data. Unlike peptides requiring continuous administration, FOXO4-DRI uses an intermittent dosing strategy. Standard research protocols typically use 10-15mg per day for 2-3 consecutive days, followed by weeks or months of observation. Conservative protocols might use 5-10mg per day for 2-3 days, while advanced protocols may use 15-20mg per day for 3 days. The foxo4 dri dosage chart shows that most research uses a 3-day treatment cycle: Day 1 (10-15mg), Day 2 (10-15mg), Day 3 (10-15mg), for a total of 30-45mg per cycle. After this 3-day treatment, there’s an observation period of 3-6 months before considering another cycle. The foxo4-dri dosage can be calculated based on body weight, with research suggesting approximately 0.1-0.2 mg/kg per administration. For a 70kg person, this would be 7-14mg per dose. The foxo4-dri human dosage used in early trials has varied, generally in the range of 5-20mg per administration. The intermittent dosing strategy is crucial – senolytic effects don’t require continuous peptide presence. The short treatment triggers senescent cell apoptosis, and clearance and regeneration occur over the following weeks. Use PrymaLab’s Peptide Calculator for precise dosing calculations. When you buy foxo4-dri from PrymaLab, detailed dosing protocols and guidelines are included.
The foxo4 dri side effects profile is generally favorable based on available research, though human data remains limited. The most common side effects are mild injection site reactions including redness, slight swelling, and minor discomfort that typically resolve within 24-48 hours. Some subjects report mild fatigue during or shortly after the 3-day treatment cycle, possibly related to immune system activation during senescent cell clearance. Occasional mild headaches have been reported, usually self-resolving within days. Rare instances of mild gastrointestinal symptoms like nausea have been noted. Importantly, the foxo4-dri side effects do NOT include the significant hematological effects (like low platelet counts) seen with some other senolytics like navitoclax. Preclinical research showed no significant organ toxicity, good long-term tolerability, and no cumulative toxicity with repeated cycles. The foxo4-dri senolytic peptide showed high selectivity for senescent cells with minimal effects on healthy cells – a crucial safety advantage. Laboratory changes may include temporary increases in markers of cell death (expected with senolytic activity) and mild transient changes in liver enzymes that typically self-resolve. The intermittent dosing strategy (just 3 days of treatment followed by months off) contributes to the favorable safety profile by limiting exposure duration. When researchers buy foxo4-dri from PrymaLab, comprehensive safety information and monitoring guidelines are provided.
You can buy foxo4-dri for research purposes from PrymaLab, a trusted supplier of pharmaceutical-grade research peptides. Our FOXO4-DRI 10MG vials contain 99% pure peptide verified by third-party testing, ensuring reliable and reproducible research results. Each vial arrives as lyophilized powder for maximum stability during shipping and storage. When you buy foxo4-dri peptide from PrymaLab, you receive comprehensive documentation including certificates of analysis, reconstitution instructions, dosing guidelines including our foxo4 dri dosage chart, and safety information. We also provide research support resources including our Peptide Calculator for accurate dosing calculations and bacteriostatic water for proper reconstitution. Fast, discreet shipping ensures your research materials arrive quickly and securely. FOXO4-DRI for sale at PrymaLab is intended for research purposes only and is not for human consumption outside approved research settings. The foxo4 dri price is competitive, and we offer support for researchers designing senolytic protocols. Our foxo4 peptide for sale meets the highest quality standards for serious longevity and anti-aging research. All our peptides for sale come with full quality documentation and research support.
The foxo4-dri human trials represent some of the most exciting developments in longevity research, though published data remains limited. Early human studies, primarily conducted in the Netherlands, have shown promising preliminary results. While detailed published data is limited, reports from these trials suggest improvements in kidney function markers in aged subjects, enhanced hair growth and quality (suggesting improved stem cell function), better physical performance and stamina, improvements in various age-related biomarkers, and subjective improvements in energy and well-being. The foxo4-dri human trials have used various dosing regimens, typically involving 2-3 days of treatment followed by observation periods of several months. Safety monitoring has shown generally good tolerability with mostly mild and transient side effects. These early human results, while preliminary, suggest that the impressive preclinical findings in aged mice may translate to humans. The trials have demonstrated that foxo4-dri senolytic peptide can be administered safely to humans and may produce measurable benefits. However, larger, more comprehensive human trials are needed to fully establish efficacy and optimal protocols. The foxo4 dri human trials data available so far is encouraging and supports continued research into this promising senolytic compound. Researchers interested in contributing to the growing body of human data can buy foxo4-dri from PrymaLab for approved research studies.
FOXO4-DRI compares favorably to other senolytic compounds in several important ways. Compared to dasatinib + quercetin (D+Q), the most studied senolytic combination, foxo4-dri senolytic peptide offers superior selectivity for senescent cells through its targeted mechanism (disrupting FOXO4-p53 interaction vs D+Q’s broader pathway effects), potentially fewer side effects due to greater selectivity, and demonstrated efficacy in both preclinical and early human studies. However, D+Q has the advantage of oral administration and more extensive human safety data. Compared to fisetin, a natural senolytic compound, foxo4 dri peptide appears more potent on a per-dose basis, has a more selective mechanism, and may produce more dramatic effects, though fisetin has advantages of oral bioavailability and lower cost. Compared to navitoclax, a potent BCL-2 inhibitor with senolytic activity, FOXO4-DRI has a much better safety profile without the significant thrombocytopenia (low platelet counts) that limits navitoclax use. The foxo4-dri senolytic mechanism – targeting a specific protein-protein interaction essential for senescent cell survival – provides precision that broader-acting senolytics may lack. The peptide-based approach allows for high selectivity and potential for optimization. Some researchers explore combining foxo4 dri with other senolytics like fisetin for potentially synergistic effects. All of these senolytic approaches are available in our peptides for sale collection for comparison research.
FOXO4-DRI begins working immediately after administration, but the timeline of observable effects varies. At the cellular level, the peptide disrupts FOXO4-p53 interactions within hours of administration, and senescent cell apoptosis begins within the first 24 hours of treatment. Over the 3-day treatment cycle, progressive senescent cell elimination occurs. In the days following treatment (days 4-7), immune system clearance of apoptotic cells continues, and early reductions in inflammatory markers may be detectable. Within 1-2 weeks post-treatment, significant senescent cell clearance is evident in tissues, and reductions in SASP factors and inflammation become apparent. By 4-8 weeks, tissue regeneration and functional improvements begin to manifest, with measurable improvements in various health markers. Maximum benefits typically develop over 8-12 weeks as tissues regenerate and adapt to the reduced senescent cell burden. The foxo4-dri benefits can persist for months after a single 3-day treatment cycle, as the elimination of senescent cells creates lasting improvements in tissue health. The timeline depends on several factors including baseline senescent cell burden (higher burden may show faster initial improvements), dose used (higher doses may produce faster effects), individual factors (age, health status, tissue regenerative capacity), and specific outcomes measured (some markers improve faster than others). The intermittent dosing strategy means that a single 3-day treatment can produce benefits lasting 3-6 months or longer, after which another cycle may be considered if needed.
FOXO4-DRI safety for research use is supported by preclinical data and limited early human trials, though human data remains more limited than for some other research peptides. Preclinical research in mice has demonstrated good tolerability across a range of doses, no significant organ toxicity at research doses, good long-term safety with repeated cycles, and no cumulative toxicity. The foxo4-dri human trials, while limited, have shown acceptable safety profiles with careful monitoring, mostly mild and transient side effects, no serious adverse events reported in available data, and good overall tolerability. The foxo4-dri senolytic peptide mechanism provides inherent safety advantages through high selectivity for senescent cells with minimal effects on healthy cells, targeted disruption of a specific protein interaction rather than broad pathway inhibition, and intermittent dosing reducing total exposure. For research purposes, foxo4 dri can be used safely with appropriate precautions including careful subject screening to exclude high-risk individuals, baseline safety assessments, ongoing monitoring during and after treatment, clear protocols for managing adverse effects, and appropriate institutional oversight and informed consent. The peptide should not be used in individuals with active cancer, pregnancy or breastfeeding, severe immunodeficiency, or recent major surgery/wounds. Research protocols should include comprehensive safety monitoring and documentation. When used responsibly with proper precautions, FOXO4-DRI provides valuable research insights into senolytic interventions while maintaining acceptable safety margins. When researchers buy foxo4-dri from PrymaLab, comprehensive safety information and monitoring guidelines are provided.
It’s important to understand that FOXO4-DRI and FOXO4 are completely different entities. FOXO4 is a naturally occurring transcription factor protein in human cells that belongs to the Forkhead box O (FOXO) family. It regulates various cellular processes including stress resistance, metabolism, and cell survival. In senescent cells, FOXO4 plays a crucial role by binding to p53 and preventing apoptosis. FOXO4-DRI, on the other hand, is a synthetic peptide designed to disrupt the FOXO4-p53 interaction. The “DRI” stands for D-retro-inverso, referring to the peptide’s structure – it’s composed of D-amino acids (mirror images of natural L-amino acids) arranged in reverse sequence. This DRI modification makes the peptide highly resistant to enzymatic degradation. The foxo4-dri peptide is based on the sequence of the FOXO4 region that binds to p53, but it’s modified to be more stable and to competitively inhibit the natural FOXO4-p53 interaction. So while FOXO4 is a natural protein that keeps senescent cells alive, FOXO4-DRI is a synthetic peptide designed to eliminate senescent cells by disrupting FOXO4’s function. When researchers buy foxo4-dri, they’re purchasing the synthetic senolytic peptide, not the natural FOXO4 protein. Understanding this distinction is important for interpreting research literature and designing protocols.
Yes, foxo4-dri can potentially be combined with other longevity interventions, and this is an exciting area of research. Potential combinations include FOXO4-DRI + NAD+ precursors (like NMN or NR) for combined senolytic and metabolic/mitochondrial benefits, as NAD+ boosters may enhance cellular energy and repair while foxo4-dri senolytic peptide eliminates damaged cells. FOXO4-DRI + Rapamycin combines senolytic activity with mTOR inhibition and autophagy enhancement, potentially providing complementary anti-aging effects. FOXO4-DRI + Metformin pairs senolytic activity with metabolic benefits and potential longevity effects of metformin. FOXO4-DRI + Fisetin combines two senolytics with different mechanisms for potentially more complete senescent cell clearance. FOXO4-DRI + Resveratrol or other sirtuin activators may provide synergistic anti-aging benefits. The intermittent dosing strategy of foxo4 dri peptide (just 3 days every few months) makes it easy to combine with continuous interventions. However, combination research requires careful protocol design including consideration of potential interactions, appropriate safety monitoring, clear assessment of individual vs combined effects, and proper timing of interventions. Some combinations may be synergistic, while others might be simply additive. Research in this area is ongoing and represents an exciting frontier in longevity science. When researchers buy foxo4-dri from PrymaLab, they can access other longevity research compounds in our peptides for sale collection for combination studies.
The foxo4-dri 10mg dosing protocol typically follows an intermittent cycle approach rather than continuous administration. A standard protocol using 10mg vials would be: Treatment Cycle (Days 1-3): Day 1 – Administer one complete 10mg vial (reconstituted with 1mL bacteriostatic water), Day 2 – Administer one complete 10mg vial, Day 3 – Administer one complete 10mg vial. Total for cycle: 30mg over 3 days. Observation Period (Weeks 1-12+): Monitor for senescent cell clearance, assess improvements in health markers, allow tissue regeneration, evaluate benefits. Repeat Cycle (If Needed): Typically 3-6 months after initial cycle, can repeat with same dosing, monitor cumulative effects. The foxo4-dri 10mg vial size is convenient as it provides a complete daily dose for standard protocols. For higher doses (15mg per day), researchers would use 1.5 vials per day. For lower doses (5mg per day), half a vial per day. The simple 10mg vial size makes dosing straightforward – reconstitute with 1mL bacteriostatic water for a 10mg/mL concentration, and administer the entire 1mL volume for a 10mg dose. This eliminates complex calculations and reduces dosing errors. The foxo4-dri dosage chart provided with orders from PrymaLab includes detailed protocols for various research applications. Use PrymaLab’s Peptide Calculator for any custom dosing calculations needed.
| Weight | N/A |
|---|---|
| Dimensions | N/A |
Only logged in customers who have purchased this product may leave a review.
support@prymalab.net info@prymalab.net
30 Day return window. Satisfaction guaranteed or your money back.
All orders over %150 in value will receive free shipping.
1 review for FOXO4 10MG